title: Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.
abstract: B-cell malignancies seem to be particularly amenable to immunotherapy and as such make particularly attractive targets for adoptive T-cell therapy. Murine T cells gene-modified to express a chimeric immune receptor specific for CD19+ (aCD19z) efficiently kill CD19 B-cell lymphoma cells in vitro. aCD19z T cells also secrete high levels of interleukin-2 during culture with target cells in a CD86 independent manner. aCD19z T cells proved effective at eradicating established B-cell lymphoma in a syngeneic model system when combined with a lymphodepleting preconditioning regimen. In mice deficient of T, B, and natural killer cells (severe combined immunodeficient/Beige), aCD19z T cells efficiently eradicated long-term (13 d) established tumors with 100% of treated animals remaining tumor free for greater than 77 days. Although gene-modified CD4+ and CD8+ were both active in this setting, poor engraftment by CD8+ T cells coupled with the rigorous expansion of CD4+ cells in the Balb/c background suggests that CD4+ T cells may be playing a predominant role in lymphoma rejection in this model. Taken together, the therapeutic effectiveness of aCD19z T cells in this model supports a recently opened phase 1 trial of this receptor in non-Hodgkin lymphoma.
authors.affiliation: Department of Medical Oncology, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, UK. echeadle@picr.man.ac.uk
authors.forename: Eleanor J
authors.initials: EJ
authors.lastname: Cheadle
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hawkins
authors.forename: Hayley
authors.initials: H
authors.lastname: Batha
authors.forename: Dominic G
authors.initials: DG
authors.lastname: Rothwell
authors.forename: Garry
authors.initials: G
authors.lastname: Ashton
authors.forename: David E
authors.initials: DE
authors.lastname: Gilham
mesh_terms: D000818:Animals; D018941:Antigens, CD19 / Q000276:immunology*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D015202:Protein Engineering; D014161:Transduction, Genetic
chemical_list: D018941:Antigens, CD19; D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide